Hologic to Showcase Advancement Simplifying Removal of Large Intrauterine Pathology at AAGL

  Hologic to Showcase Advancement Simplifying Removal of Large Intrauterine
                              Pathology at AAGL

Company to Introduce Minimally Invasive MyoSure XL Fibroid Removal Device

PR Newswire

BEDFORD, Mass., Nov. 5, 2012

BEDFORD, Mass., Nov. 5, 2012 /PRNewswire/ --Hologic, Inc. (Hologic or the
Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of
premium diagnostics, medical imaging systems and surgical products dedicated
to serving the healthcare needs of women, today announced that its suite of
gynecologic surgical products will be on display at the 41^st AAGL Global
Congress on Minimally Invasive Gynecology, November 5-9, 2012, in Las Vegas,
NV. The American Association of Gynecologic Laparoscopists (AAGL) is the
leading association promoting minimally invasive gynecologic surgery among
surgeons worldwide.

This year, Hologic will debut the MyoSure XL fibroid removal device an
addition to the MyoSure product line. Both the MyoSure tissue removal system
and MyoSure XL fibroid removal device provide incisionless treatment options
for relieving abnormal uterine bleeding (AUB) symptoms and infertility caused
by endometrial polyps and submucosal fibroids. With the MyoSure XL device a
physician is able to hysteroscopically remove a 5cm fibroid in less than 15
minutes.

"We are pleased to share real-world and practical insights that deepen the
understanding of the safety and efficacy of our MyoSure product family as well
as our NovaSure endometrial ablation system at AAGL this year," said Shacey
Petrovic, Vice President and General Manager of Hologic's GYN Surgical
Products Division. "These products provide options to effectively treat
polyps, fibroids and abnormal uterine bleeding without requiring major surgery
and underscore our unwavering commitment to advancing women's health."

Abnormal uterine bleeding (AUB) is bleeding that is not part of a woman's
normal menstrual cycle. Today, an estimated 20 percent of all women experience
AUB. The majority of women are not aware that AUB is a real medical condition
that can range from extremely heavy bleeding to irregular periods (outside the
usual 21 to 28-day monthly cycle). Because women are reluctant to talk about
changes in their periods, they often suffer in silence unnecessarily and
forego treatment for years. Hologic's MyoSure and NovaSure procedures are
minimally invasive and are designed to treat women with abnormal uterine
bleeding.

In addition to the MyoSure product line, Hologic will display the full range
of products in its gynecologic surgical suite.

  oNovaSure Endometrial Ablation System: Since 2001, more than 1.5 million
    women have been treated with the NovaSure procedure to reduce or eliminate
    heavy menstrual bleeding, without hormones or an invasive hysterectomy.
    Earlier this year, Hologic launched a patient-centered campaign –
    changethecycle.com – using best-selling author Vicki Iovine ("The
    Girlfriend's Guide to Pregnancy") to connect former patients with future
    patients to answer questions about heavy periods and NovaSure.
  oAquilex Fluid Control System: The Aquilex fluid control system was
    developed to simplify hysteroscopic procedures such as the MyoSure
    procedure. This high-performance system is designed to minimize the risk
    of inaccurate deficit readings and maintains constant uterine cavity
    distention throughout the MyoSure procedure.
  oTower-free Hysteroscopy System (THS): The THS is designed to meet the
    diverse diagnostic and treatment needs of the gynecologist's office. This
    versatile platform is compatible with Hologic's full range of gynecologic
    solutions, including planning for NovaSure and MyoSure procedures.

For more information about Hologic's gynecologic surgical products,
presentations and sessions at AAGL, please visit booth 413.

About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium
diagnostic products, medical imaging systems, and surgical products.The
Company operates four core business units focused on breast health,
diagnostics, GYN surgical and skeletal health.With a comprehensive suite of
technologies and a robust research and development program, Hologic is
committed to improving lives.The Company is headquartered in Massachusetts.
For more information, visit www.hologic.com.

Forward-Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks
and uncertainties, including statements about the use of the NovaSure,
MyoSure, THS and Aquilex systems. There can be no assurance the systems will
achieve the benefits described herein and that such benefits will be
replicated in any particular manner with respect to an individual patient as
the actual effect of the use of these systems can only be determined on a
case-by-case basis depending on the particular circumstances and patient in
question. Hologic expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to the data or statements presented herein
to reflect any change in the Company's expectations or any change in events,
conditions or circumstances on which any such data or statements are based.
Certain factors that could adversely affect the Company's business and
prospects are described in Hologic filings with the Securities and Exchange
Commission.

Hologic, Aquilex, MyoSure, NovaSure and THS are trademarks and/or registered
trademarks of Hologic, Inc., and/or its subsidiaries in the United States
and/or other countries.

Contacts:
Pat Hall                            Stephanie Cilibrasi
Director of Corporate               Product Manager
Communications
Hologic, Inc.                       Hologic, Inc.
Tel: 781-999-7463                   Tel: 339-221-3292
Pat.Hall@hologic.com                Stephanie.Cilibrasi@hologic.com 

SOURCE Hologic, Inc.

Website: http://www.hologic.com
 
Press spacebar to pause and continue. Press esc to stop.